AbbVie Reports the Acquisition of Celsius Therapeutics
Shots:
- AbbVie has purchased all the outstanding shares of Celsius Therapeutics for an aggregate of $250M in cash, contingent upon certain customary adjustments
- The acquisition adds Celsius' CEL383, which has completed the P-I single ascending dose trial assessing its safety, tolerability & PK profile among healthy subjects for treating IBD, to AbbVie’s portfolio
- CEL383, a TREM1 targeting antibody, has demonstrated a decrease in multiple inflammatory mediators relevant to inflammatory conditions by inhibiting TREM1 signaling in non-clinical studies
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie’s Epkinly (epcoritamab-bysp) Receives the US FDA’s Accelerated Approval to Treat R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
